Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.18M Sell
220,000
-1,033,400
-82% -$27.5M ﹤0.01% 1802
2025
Q4
$31.2M Buy
1,253,400
+778,400
+164% +$19.6M 0.01% 862
2025
Q3
$12.1M Sell
475,000
-645,100
-58% -$15.9M 0.01% 1367
2025
Q2
$27.2M Sell
1,120,100
-314,500
-22% -$7.33M 0.01% 823
2025
Q1
$36.4M Buy
1,434,600
+381,400
+36% +$9.98M 0.02% 694
2024
Q4
$27.9M Sell
1,053,200
-501,300
-32% -$13.6M 0.02% 780
2024
Q3
$45M Buy
1,554,500
+752,600
+94% +$22M 0.03% 578
2024
Q2
$22.4M Buy
801,900
+259,100
+48% +$7.13M 0.01% 831
2024
Q1
$15.1M Sell
542,800
-75,500
-12% -$2.1M 0.01% 1029
2023
Q4
$17.8M Buy
618,300
+67,800
+12% +$2.05M 0.01% 914
2023
Q3
$18.3M Buy
550,500
+158,200
+40% +$5.59M 0.01% 807
2023
Q2
$14.4M Sell
392,300
-291,000
-43% -$11.3M 0.01% 969
2023
Q1
$27.9M Sell
683,300
-1,049,900
-61% -$45.3M 0.02% 647
2022
Q4
$88.8M Buy
1,733,200
+1,042,100
+151% +$50M 0.07% 253
2022
Q3
$30.2M Buy
691,100
+81,500
+13% +$3.96M 0.02% 578
2022
Q2
$32M Sell
609,600
-514,400
-46% -$26.2M 0.02% 573
2022
Q1
$58.2M Sell
1,124,000
-1,747,800
-61% -$90.7M 0.04% 444
2021
Q4
$170M Buy
2,871,800
+871,100
+44% +$43.2M 0.09% 199
2021
Q3
$86M Buy
2,000,700
+235,600
+13% +$10.4M 0.05% 332
2021
Q2
$69.1M Buy
1,765,100
+253,400
+17% +$9.85M 0.04% 414
2021
Q1
$54.8M Sell
1,511,700
-1,794,300
-54% -$63.7M 0.04% 464
2020
Q4
$122M Buy
3,306,000
+1,501,552
+83% +$55.1M 0.07% 247
2020
Q3
$62.8M Buy
1,804,448
+624,390
+53% +$21.9M 0.04% 370
2020
Q2
$36.6M Sell
1,180,058
-431,192
-27% -$14.6M 0.03% 515
2020
Q1
$49.9M Buy
1,611,250
+246,425
+18% +$8.4M 0.05% 357
2019
Q4
$50.7M Sell
1,364,825
-304,395
-18% -$10.8M 0.04% 504
2019
Q3
$56.9M Buy
1,669,220
+826,969
+98% +$30.1M 0.05% 399
2019
Q2
$34.6M Sell
842,251
-1,084,145
-56% -$43M 0.03% 612
2019
Q1
$77.6M Sell
1,926,396
-152,514
-7% -$6.11M 0.07% 245
2018
Q4
$86.1M Buy
2,078,910
+6,535
+0.3% +$271K 0.09% 221
2018
Q3
$86.7M Buy
2,072,375
+159,787
+8% +$6.15M 0.08% 226
2018
Q2
$65.8M Buy
1,912,588
+253,592
+15% +$8.67M 0.06% 270
2018
Q1
$55.9M Sell
1,658,996
-16,232
-1% -$558K 0.05% 351
2017
Q4
$57.6M Sell
1,675,228
-867,336
-34% -$29.6M 0.05% 384
2017
Q3
$86.1M Buy
2,542,564
+1,358,922
+115% +$43.7M 0.07% 233
2017
Q2
$37.7M Sell
1,183,642
-280,891
-19% -$8.86M 0.03% 462
2017
Q1
$47.5M Sell
1,464,533
-3,170,432
-68% -$100M 0.04% 378
2016
Q4
$143M Buy
4,634,965
+1,814,145
+64% +$55.4M 0.13% 127
2016
Q3
$90.6M Sell
2,820,820
-305,555
-10% -$10.2M 0.08% 210
2016
Q2
$104M Sell
3,126,375
-120,156
-4% -$3.83M 0.11% 169
2016
Q1
$91.3M Sell
3,246,531
-4,186,488
-56% -$120M 0.1% 173
2015
Q4
$228M Sell
7,433,019
-1,056,002
-12% -$33.2M 0.23% 62
2015
Q3
$253M Buy
8,489,021
+5,301,409
+166% +$170M 0.24% 50
2015
Q2
$101M Sell
3,187,612
-9,812,846
-75% -$320M 0.09% 198
2015
Q1
$429M Buy
13,000,458
+3,235,780
+33% +$103M 0.41% 24
2014
Q4
$289M Buy
9,764,678
+1,788,744
+22% +$51.3M 0.26% 43
2014
Q3
$224M Buy
7,975,934
+2,491,972
+45% +$69.9M 0.2% 67
2014
Q2
$154M Buy
5,483,962
+3,291,958
+150% +$93.8M 0.15% 110
2014
Q1
$66.8M Buy
2,192,004
+244,634
+13% +$7.29M 0.07% 245
2013
Q4
$56.6M Sell
1,947,370
-2,197,696
-53% -$64M 0.05% 335
2013
Q3
$113M Sell
4,145,066
-269,929
-6% -$7.34M 0.11% 155
2013
Q2
$117M Buy
+4,414,995
New +$122M 0.12% 123

Other funds holding PFE

Citigroup's PFE Position: Q1 2026 in Review

Citigroup increased its Pfizer (PFE) stake by 8.6% in Q1 2026, buying an estimated $32.7M and bringing the position to 15,493,259 shares worth $435M. The position accounts for 0.19% of the portfolio, ranked #98.

Citigroup first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Citigroup held 15,493,259 shares of Pfizer worth $435M as of Q1 2026.
  • Citigroup bought 1,228,140 Pfizer shares in Q1 2026, an estimated $32.7M.
  • Pfizer made up 0.19% of Citigroup's portfolio in Q1 2026, its #98 holding.
  • Citigroup first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.